



TRUPCR[®]

www.3blackbio.com

ANNUAL REPORT
2021-2022



3B BlackBio Biotech India Ltd.

NOTICE OF ANNUAL GENERAL MEETING


NOTICE is hereby given that the ANNUAL GENERAL MEETING of M/s 3B BLACKBIO BIOTECH INDIA LIMITED, will be held at the Registered office of the Company at 7-C, Industrial Area, Govindpura, Bhopal 462023 on Thursday , the 22nd September, 2022 at 1:30 P.M. to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended 31st March, 2022 together with the Reports of Board of Directors and Auditors thereon.
2. To appoint a Director in place of Mr. Nikhil Kuber Dubey (DIN: 00538049), Wholetime Director, who retires by rotation and being eligible, offers himself for re-appointment.
3. To appoint auditors and fix their remuneration for the year ending on 31st March, 2022.
4. To approve final dividend of 250%, on equity shares for the financial year 2021-22.

BY ORDER OF THE BOARD OF DIRECTORS




DHIRENDRA DUBEY
CHAIRMAN & DIRECTOR
DIN: 01493040

Place: Bhopal
Dated: 27-05-2022

Registered Office:
7-C, Industrial Area,
Govindpura, Bhopal-462 023.
CIN: U24232MP2010PTC024717
Ph: 91-755-4077847
Fax : 91-755-2580438 Website: www.3bblackbio.com
Email: info@3bblackbio.com

Notes:

1. An explanatory statement pursuant to section 102 of the Companies act, 2013 setting out all material facts is annexed hereto.
2. A member entitled to attend and vote at the meeting is entitled to appoint another person as his proxy to attend and vote instead of himself/herself and a proxy need not be a member of the Company.
3. The instrument appointing the proxy should however, be deposited at the Registered Office of the Company not less than forty – eight hours before the commencement of the meeting.
4. Members who require more information about the accounts are requested to inform the Company 7days in advances their intention to do so, that the proper records relating thereto may be made available.
5. Members are requested to produce the attendance slip duly signed.

DETAILS UNDER SS-2 OF SECRETARIAL STANDARDS ON GENERAL MEETING REGARDING APPOINTMENT OR RE-APPOINTMENT OF THE DIRECTORS

Name of the Director	Mr. Nikhil Kuber Dubey
Category	Executive, Promoter
DIN	00538049
Date of Birth	07/11/1970
Date of First Appointment	12/11/2010
Qualifications	B.Sc
Brief Profile and Expertise in Specific functional Area	Mr. Nikhil Kuber Dubey aged 51 years is Whole Time Director of the Company, is an entrepreneur. He is looking after Finance, Banking and Taxation. He has successfully attended several programmes for organization business leadership.
List of other Directorships held in Public Limited Companies	Kilpest India Limited, Holding Company
Chairman/ Member of committees of the Board of Companies of which he is a director	Kilpest India Limited Member: Audit Committee and Stakeholders Relationship Committee
Shareholding as on 31-03-2022	10000 equity shares
Number of Meeting of Board attended during the year and other directorship etc.	9 in M/s 3B BLACKBIO BIOTECH INDIA LIMITED, SUBSIDIARY COMPANY. 12 in M/s KILPEST INDIA LIMITED, HOLDING COMPANY.
Membership, Chairman of Committees in the Outside Companies	Nil
Remuneration last drawn	Rs. 18.00 Lacs Per Annum + Commission of 1.5% of net profit
Relationship with other Directors/KMP etc	Brother of Mr. Dharendra Dubey, Whole-Time Director

DIRECTORS' REPORTS

To the Members of
3B BlackBio Biotech India Limited

Your Directors take pleasure in presenting to you their Twelfth Annual Report on the business and operations of your Company along with the Audited Financial Statements, for the Financial Year ended March 31, 2022.

1. FINANCIAL RESULTS:

The Company's financial performance for the year ended 31st March 2022 is summarized below:

(Rs. in Lacs)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
Total Revenue	7358.89*	21705.61*
Less: Expenditure	3081.02	6668.89
Less: Depreciation	38.11	41.53
Add: Exceptional item	0.00	0.00
Profit/(loss)before Tax(PBT)	4239.76	14995.19
Less: Tax Expense		
Current Tax	981.86	3742.06
Deferred Tax	74.94	31.28
Previous year Income Tax	0	6.76
Net Profit After tax	3182.96	11215.08

*Net of GST

2. INDUSTRY POTENTIAL- MOLECULAR DIAGNOSTICS

The current market size for next generation diagnostics (including molecular diagnostics) in India between Rs. 1000 – Rs. 1100 crores and growing around 15%.

3. COVID-19 and its Impact

During FY 2021-22, the Coronavirus ('COVID-19') pandemic continued to cause significant disruption to the world economy with new and highly infectious variants like Omicron and Delta spreading at unprecedented rates. The country faced lot of difficulties due to higher infections.

Keeping the physical safety and mental well-being of our employees on top priority, we implemented several precautionary measures and initiatives to provide necessary support to our employees during these testing times. We continued the implementation of safety

guidelines to address employee and customer queries; issued regular COVID-19 safety advisories to employees Your Company managed to navigate well through the difficult situation with support of its employees and the Management. There were no disruptions to the Operations of the Company.

However, the Board and the Management continues to closely monitor the situation as it evolves and do it's best to take all necessary measures, in the interests of all stakeholders of the Company and will change our plans where needed in the best interests of our employees, customers and partners.

4. PERFORMANCE OF THE COMPANY:

1) Presence in Medlab Middle East 2022:

The company participated in Medlab Middle-East 2022 held in Dubai during 24th- 27th January 2022 that garnered a lot of interest from various end-users and prospective partners for our products.

We have a gradually expanding a foothold in the international markets which was evident from the meetings that happened during the Medlab event. We were able to meet and engage in discussions about prospective business opportunities in the Middle-East and African region.


Company will continue to participate in more International events.

2) ISO 13485:2016 Accreditation by BSI, UK:

On 2nd February 2022, the company 3B BlackBio Biotech India Limited got the ISO 13485:2016 Accreditation by BSI, UK. BSI is among the most respected and reputable management systems certification bodies in the world and are accredited by around 20 local and international bodies.

3) International Business:

In the Year 2021-22, the company focused on expanding our international business. As of now, our products have been well-accepted in more than 25 countries across the world. With the export restriction removed in the 2nd quarter of FY 21-22, we fast paced our marketing strategy for the international customers which is evident from the figures of exports done.



The company has made great achievements in terms of sales & profits, the molecular diagnostic business shall continue to grow well for few years from now; with new product addition (with continuous R & D efforts), new customer addition, and venturing into export markets.

Your Company's products command a very good brand image in the market, and the company is regarded by prominent labs as a reliable solution provider at par to the foreign multinational.

The company is on the verge of becoming a market leader in India, although the sales came down to Rs. 6682.78 lakhs from Rs. 21421.35 lakhs and EBITDA came down to Rs. 4277.86 lakhs from Rs. 15036.71 lakhs; PAT came down to Rs. 3182.96 lakhs from Rs. 11215.08 lakhs, the main reason being drastic reduction in the COVID kits prices. The figures of Year 2020-21 cannot be compared due to COVID-19 revenue which was a one-time event.

5. SHARE CAPITAL

The paid up Equity Share Capital stood at Rs 1, 02, 75,000/- on 31st March, 2022. During the year under review, the Company has not issued any shares. The Company has not issued shares with differential voting rights. It has neither issued employee stock options nor sweat equity shares and does not have any scheme to fund its employees to purchase the shares of the Company.

6. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND

As per the provisions of Section 125(2) of the Companies Act, 2013, no unpaid dividend was required to be transferred to the Investor Education and Protection Fund during the year.

7. CORPORATE SOCIAL RESPONSIBILITY:

Your Company has constituted an independent Corporate Social Responsibility Committee pursuant to section 135 of the Companies Act, 2013.

COMPANY'S PHILOSOPHY:

The Company's CSR philosophy is based on the belief that a successful business can develop only by creating a prosperous society around. Reaching out to deprived communities is part of the Company's vision and its CSR initiatives aim at supplementing government endeavors' to help the citizens in the vicinity to achieve better living standards and good quality of life. The Company has been engaging with civil society, public at large through dissemination of its CSR initiatives.

Corporate Social Responsibility Policy:

The Company has adopted a Corporate Social Responsibility Policy as required under section 135 of the Companies Act, 2013 for the activities covered under Schedule VII of the Act. The CSR Policy may be accessed on the Company's website i.e. www.3bblackbio.com

The Annual Report on CSR activities is annexed herewith marked as Annexure C.

8. DETAILS OF UNCLAIMED DIVIDEND

In order to help Members ascertain the status of unclaimed dividends, the Company has uploaded the information in respect of unclaimed dividends for the financial year ended 31st March, 2021 as on the date of the previous AGM i.e. 22nd September, 2021 (11th AGM) on the website of Investor Education and Protection Fund, at www.iepf.gov.in.

9. PUBLIC DEPOSITS

The Company has not accepted any deposits from the public during the year under review. No amount on account of principal or interest on deposits from the public was outstanding as on March 31, 2022.

10. TRANSFER TO RESERVES:

The balance of Profit and Loss Account after adjusting income tax, interim dividend and final dividend is proposed to be transferred to Reserves and Surplus.

11. CHANGES IN THE NATURE OF BUSINESS, IF ANY:

There was no change in the nature of business of the Company during the financial year ended 31st March 2022. Further there have been no material changes and commitments, if any affecting financial position of the Company from financial year end and till the date of this report.

12. EXPANSION:

Our Rapid Kit manufacturing plant is ready for trial runs with annual capacity of over 3 million tests & we are optimizing the products in R&D which have market potential, other than COVID Testing Kits.

On 2nd February 2022, after extensive efforts by the company, our "TRURAPID® COVID-19 Ag Test" has been approved by ICMR (Indian Council of Medical Research).

COVID Rapid Antigen Test is ready and ICMR approved, but demand is very less at present with very low realization. Considering this fact, company will launch some novel products in FY 2022-23, which are under R&D Stage.

13. DIRECTORS

In accordance with the provisions of the Companies Act, 2013, Mr. Nikhil Kuber Dubey, Director retiring by rotation and being eligible, offered himself for re-appointment at the ensuing Annual General Meeting.

A resolution seeking shareholders' approval for his re-appointment along with other required details forms part of the Notice of Annual General Meeting.

DECLARATION OF INDEPENDENCE

Independent Director has given declaration that he meets the criteria of independence as prescribed under the provisions of the Companies Act, 2013 read with schedules and rules. In the opinion of the Board, he fulfills the conditions of independence as specified in the Act and the Rules made thereunder and are independent of the management. There has been no change in the circumstances affecting his status as Independent Director of the Company.

The Board is of the opinion that the Independent Director of the Company possess requisite qualifications, experience and expertise in the fields of science and technology, digitalisation, human resources, strategy, auditing, tax and risk advisory services, financial services, corporate governance, etc. and that they hold highest standards of integrity.

14. RISK MANAGEMENT

The Company has a well-defined risk management framework in place to identify, evaluate, and monitor business risks and challenges across the Company as well as to identify new and emergent risks. The Company's success as an organization largely depends on its ability to identify opportunities and leverage them while mitigating the risks that arise while conducting its business. Your Directors continually evaluate the risks faced by the Company which could affect its business operations or threaten its existence. The Company takes appropriate risk containment measures and manages the same on an ongoing basis. The Company has adopted a Risk Management Policy pursuant to Section 134 of the Act.

15. INFORMATION UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

Your Directors further state that during the year under review, there was no cases filed pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

16. DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF

During the period under review, the Company has not made any such valuation.

17. AMALGAMATION

We have received the approval from BSE vide their letter "Observation Letter" on 3rd February, 2022. After the BSE and SEBI approval, we have now applied for the petition for amalgamation to NCLT for the scheme of amalgamation on 9th May, 2022. We are hoping this process will now accelerate and complete in few months depending on NCLT. Your company is working on faster approval of the scheme, which should result in to unlocking the value of Material Subsidiary i.e. 3B BlackBio Biotech India Ltd.

RATIONALE FOR AMALGAMATION

- a. The management prime focus is to run and grow the Diagnostic business. Hence, 3B BlackBio is being amalgamated with Kilpest and all assets (land, building and equipment) of Kilpest will be dedicated to diagnostic business.
- b. The Amalgamated company will be grown not only in Molecular Diagnostics, but also in other fields like Rapid Cards (based on Antigen and Antibodies) and other related scalable business verticals.
- c. Kilpest will continue to run as an Independent division for some time till the company finds a suitable buyer for its Agrochemical Division to sell its brands and other intangible assets.
- d. As a result of amalgamation of 3B BlackBio (Diagnostic business) with Kilpest, finally we would have a single company to be renamed as 3B BlackBio Dx Ltd. which will be

classified as a Diagnostic company and will have over 90% of revenues from Diagnostics Business. The listed company would be renamed as 3B BlackBio Dx Ltd. in order to solely focus on growth and development of Diagnostic business.

- e. Gradually, all immovable assets including land (2 acres) and factory building would be fully utilized for the growth and expansion of 3B BlackBio Dx Ltd. and Research & Development Activities in the field of Diagnostic business.

18. SECRETARIAL AUDITOR

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors of the Company had appointed M/s P.K. Rai & Associates, Practicing Company Secretary to undertake the Secretarial Audit of M/s 3B BlackBio Biotech India Limited, material subsidiary of M/s Kilpest India Limited for the year ended 31st March, 2022. The Secretarial Audit Report for the Financial Year ended 31st March, 2022 is annexed as Annexure B and does not contain any qualification, reservation, adverse remark or disclaimer

The Company has complied with the applicable Secretarial Standards issued by the Institute of Company Secretaries of India.

19. DETAILS OF SUBSIDIARY, JOINT VENTURE OR ASSOCIATE COMPANIES

On 3rd November 2021, 3B BlackBio Biotech India Limited, the subsidiary of Kilpest India Limited entered into a Joint Venture Agreement with its European Distributor, HS Biolabs Limited based in Manchester, United Kingdom.

With this Joint Venture, 3B BlackBio became the major shareholder of HS Biolabs Limited and thereby forming its European subsidiary by acquiring 70% shares in the new subsidiary (for GB£ 1,015,000.00) i.e., 10% shares were acquired from existing promoter and 60% shares were allotted via. issue of fresh capital by the company. HS Biolabs Limited has been rebranded as TRUPCR Europe Ltd.

The initial investment is being used for:

- set up of separate facilities for R&D and production;
- sales & marketing team to cover Europe;
- R&D and production Team;
- expand the marketing efforts in the European region;
- for getting TRUPCR Europe Limited certified as Manufacturing Site-II under ISO 13485:2016

With over a decade of experience in R&D, we have developed more than 100 tests for molecular testing and many more are in the pipeline.

Honored with "Outstanding Achievement Award" in 2022 for the Second Time after 2017 for outstanding achievement in Research & Development by "Federation of Madhya Pradesh Chambers of Commerce"

Largest suppliers of COVID-19 RT PCR Tests in India to have supplied over 15 Million tests to more than 400 labs across 80 cities of India.

"TRUPCR®" is our registered brand name for Real-Time PCR based molecular diagnostic kits & "TRUNGS®" is our registered brand name for NGS based molecular testing kits. "TRURAPID®" is our registered brand name for Lateral Flow assays.

Our vision is that in 2022, we would be able to realize major success from the subsidiary and efforts by an increase in export sales and R&D outcomes.

Proposed Achievements

- a) Products "Made in UK" – The new subsidiary will enable us to manufacture TRUPCR® Kits in the UK which would boost our product acceptability and reach, especially within Europe.
- b) Increased Revenue – The European subsidiary will focus on becoming accredited for ISO 13485:2016; this will enhance customer service allowing the assays to be developed, supplied and supported quickly throughout the European region, increasing the revenue stream.
- c) R&D – We plan to start R&D work with collaborations with European universities which will add value to the business in the long run.

20. EXTRACT OF ANNUAL RETURN

The details forming part of the extract of the Annual Return as on 31st March 2022 in form MGT-9 in accordance with Section 92(3) of the Companies Act, 2013 read with Companies (Management and Administration) Rules, 2014, are set out herewith as Annexure I to this Report.

Further pursuant to Section 92(3) of the Act and Rule 12 of the Companies (Management and Administration) Rules, 2014 read with Section 134(3)(a) of the Act, the Annual Return in Form MGT-7 as on 31st March 2022 is available on the Company's website at www.3bblackbio.com

21. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS

No significant and material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

22. MEETINGS OF BOARD OF DIRECTORS/ GENERAL BODY MEETING

During the financial year ended March 31, 2022, nine (9) Board meetings were held. The intervening gap between any two board meetings was within the period prescribed under the Companies Act, 2013.

23. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016

During the period under review, the Company has not made any application or any proceeding is pending under the Insolvency and Bankruptcy Code, 2016.

24. AUDITORS:

M/s R.C.Baheti & Co. Chartered Accountants, retire at the ensuing Annual General Meeting and are eligible for reappointment.

25. AUDITORS' REPORT:

The Report is given by the Auditors on the financial statements of the Company. There has been no qualification, reservation, adverse remarks or disclaimer given by the Auditors in their Report. The notes forming part of the accounts are self-explanatory and do not call for any further clarifications under Act.

26. PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE

The Company is committed to provide a safe and conducive work environment to its employees, during the year under review. The Board further states that during the year under review, there were no cases filed pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

27. HUMAN MANAGEMENT:

Our Employees are most valuable assets of the Company. We encourage innovation, meritocracy and the pursuit of Excellence. We have setup a scalable recruitment and human resources management process, which enables us to attract and retain employees. Cordial employee relations were maintained throughout the year in Company. The directors express their appreciation for the contribution made by employees to operations of the Company during the year.

28. PARTICULARS OF LOANS GIVEN, INVESTMENTS MADE, GUARANTEES GIVEN AND SECURITIES PROVIDED

The Company has not given any loans, or provided any guarantee or security as specified under Section 185 of the Act and the Company has not provided any security as specified under Section 186 of the Act. and hence the said provision is not applicable.

29. INTERNAL FINANCIAL CONTROLS

The Directors have laid down internal financial controls to be followed by the Company for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and the completeness of the accounting records and the timely preparation of reliable financial information. During the year, such controls were tested and no reportable material weakness in the design or operation were observed.

30. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS OTHER THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL GOVERNMENT

The Statutory Auditors and Secretarial Auditors of the Company have not reported any frauds to the Audit Committee or the Board of Directors under Section 143(12) of the Act, including rules made thereunder

31. INSURANCE:

The assets of Company are adequately insured against loss of fire, riot, earthquake, flood etc. and other risks which are considered necessary by the Management.

32. MATERIAL CHANGES & COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRING AFTER BALANCE SHEET.

No material changes and commitments affecting the financial position of the company occurred between the ends of this financial year to which these financial statements relate on the date of this report.

33. DIVIDEND

The Board of Directors at their meeting held on 27th May, 2022, recommended a Final Dividend of 250% (Rs 25.00 per fully paid up equity shares of Rs 10/- each), for the financial year ended 31st March, 2022. The dividend payout is subject to approval of members at the ensuing Annual General Meeting.

The Board of Directors had already paid a special interim dividend of Rs. 75.00/- per equity share of face value of Rs. 10/ each for the FY 2021-22 in the last Annual General meeting dt. 22-09-2021.

34. CREDIT RATING OF SECURITIES

The Company is not required to obtain credit rating of securities and hence no credit rating of securities was obtained by the Company.

35. No Default

The company has not defaulted in payment of interest and/or repayment of loans to any of the financial institutions and/or banks during the year under review.

36. COMMITTEES

The Company is not required to constitute Audit Committee or Nomination and Remuneration Committee.

37. BOARD EVALUATION

Being an unlisted private Company, the formal annual evaluation by the Board of its performance and that of its committees and individual Directors are not mandatory.

38. DIRECTORS' RESPONSIBILITY STATEMENT:

Based on the framework of internal financial controls and compliance systems established and maintained by the Company, work performed by the Internal, Statutory and Secretarial Auditors, including audit of the internal financial controls over financial reporting by the Statutory Auditors and the reviews performed by Management and the relevant Board Committees, including the Audit Committee, the Board is of the opinion that the Company's internal financial controls were adequate and effective during FY 2021-22.

The Statement of the Directors' Responsibility on Annual Accounts of the Company referred to in Sections 134(3)(c) and 134(5) of the Companies Act, 2013 shall state that -

- 1) that in preparation of annual accounts, the applicable accounting standards have been followed and there are no material departures;
- 2) that directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of profits and loss of the Company for that period;

- 3) that the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding assets of the Company and for preventing and detecting fraud and other irregularities;
- 4) that the directors had prepared Annual Accounts on a going concern basis; and
- 5) the directors, have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and
- 6) the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

39. ACKNOWLEDGEMENT:

The Directors hereby acknowledge the dedicated and loyal services rendered by the employees of the Company during the year. They would also like to place on record their appreciation for the continued co-operation and support received by the Company during the year from bankers, financial institutions, Government authorities, business partners, shareholders and other stakeholders without whom the overall satisfactory performance would not have been possible. The Directors look forward to continuance of the supportive relations and assistance in the future.

The Directors deeply regret the losses suffered due to the Covid-19 pandemic and place on record their sincere appreciation to all the front-line workers and those who have gone beyond their duties in battling against the pandemic.

FOR AND ON BEHALF OF THE BOARD




DHIRENDRA DUBEY
CHAIRMAN & DIRECTOR
DIN: 01493040

Place: Bhopal

Dated: 27-05-2022

Annexure -A

FORM NO. MGT 9
EXTRACT OF ANNUAL RETURN

As on financial year ended on 31.03.2022

Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company (Management & Administration) Rules, 2014.

I. REGISTRATION & OTHER DETAILS:

1.	CIN	U24232MP2010PTC024717
2.	Registration Date	12-11-2010
3.	Name of the Company	3B BLACKBIO BIOTECH INDIA LIMITED
4.	Category/Sub-category of the Company	Non Government Company Limited by Shares
5.	Address of the Registered office & contact details	7 C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462023 (MP) PH-0755-4077847 E-mail-info@3bbblackbio.com
6.	Whether listed company	No (deemed Listed)
7.	Name, Address & contact details of the Registrar & Transfer Agent, if any.	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY (All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

S. No.	Name and Description of main products / services	NIC Code of the Product/service	% to total turnover of the company
1	DIAGNOSTIC KITS/ PATHOLOGICAL ENZYME	20299	100%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

Sr. No.	Name And Address Of The Company	CIN/ GLN	Holding/ Subsidiary/ Associate	% of shares held	Applicable Section
1	M/S KILPEST INDIA LIMITED, 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462023	L24211MP1972PLC001131	HOLDING	87.45	2(87)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year [As on 1-April-2021]				No. of Shares held at the end of the year [As on 31-March-2022]				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoter s									
(1) Indian									
a) Individual/ HUF									
Dhirendra Dubey	40000	0	40000	3.89	40000	0	40000	3.89	0.00
Nikhil Kuber Dubey	10000	0	10000	0.97	10000	0	10000	0.97	0.00
b) Central Govt									
c) State Govt(s)									
d) Bodies Corp.									
M/S Kilpest India Limited*	898500	0	898500	87.45	898500	0	898500	87.45	0.00
e) Banks / FI									
f) Any other									
Sub Total (A)(1)	948500	0	948500	92.31	948500	0	948500	92.31	0.00
2). Foreign									
a) NRIs – Individuals									
b) Others – Individuals									
c) Bodies Corporate									
M/S 2B BLACKBIO, S.L. SPAIN		29000	29000	2.82	0.00	29000	29000	2.82	0.00
d) Banks / FI									
e) Any other									
Sub Total (A)(2)		29000	29000	2.82	0	29000	29000	2.82	0.00
Total shareholding of Promoter (A) = (A)(1)+ (A)(2) =	948500	29000	977500	95.13	948500	29000	977500	95.13	0.00

B. Public Shareholding									
1. Institutions									
a) Mutual Funds									
b) Banks / FI									
c) Central Govt									
d) State Govt(s)									
e) Venture Capital Funds									
f) Insurance Companies									
g) FIIs									
h) Foreign Venture Capital Funds									
i) Others (specify)									
Sub-total (B)(1):-	0	0	0	0	0	0	0	0	0
2. Non-Institutions									
a) Bodies Corp.									
i) Indian									
ii) Overseas									
b) Individuals									
i) Individual shareholders holding nominal share capital upto Rs. 1 lakh									
Prateek Goel	50000	0	50000	4.87	50000	0	50000	4.87	0.00
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh									
c) Others (specify)									
Sub-total (B)(2):-	50000	0	50000	4.87	50000	0	50000	4.87	0.00
Total Public Shareholding (B)=(B)(1)+(B)(2)	50000	0	50000	4.87	50000	0	50000	4.87	0.00

C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	998500	29000	1027500	100	998500	29000	1027500	100	0

ii) Shareholding of Promoter-

S. No.	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1	M/S KILPEST INDIA LIMITED*	898500	87.45	0	898500	87.45	0	0.00
2	M/S 2B BLACKBIO, S.L. SPAIN	29000	2.82	0	29000	2.82	0	0.00
3	Mr. DHIRENDRA DUBEY	40000	3.89	0	40000	3.89	0	0.00
4	MR. NIKHIL KUBER DUBEY	10000	0.97	0	10000	0.97	0	0.00
	Total	977500	95.13	0	977500	95.13	0	0.00

iii) Change in Promoters' Shareholding (please specify, if there is no change)

S. No	Name	Shareholding		Date	Increase/Decrease in share-holding	Reason	Cumulative shareholding during the year (01.04.21 to 31.03.22)	
		No. of Shares at the beginning (01.04.21)/ End of the year (31.03.22)					No. of Shares	% of total shares of the Company
1	M/S Kilpest India Limited*	898500	87.45					
				No movement during the year				
		898500	87.45	31-03-2022				
2	M/S 2B BLACKBIO, S.L. SPAIN	29000	2.82					
				No movement during the year				
		29000	2.82	31-03-2022				
3	MR. DHIRENDRA DUBEY	40000	3.89					
				No movement during the year				
		40000	3.89	31-03-2022				

4	MR. NIKHILKUBER DUBEY	10000	0.97					
				No movement during the year				
		10000	0.97	31-03-2022				

**iv) Shareholding Pattern of top ten Shareholders:
(Other than Directors, Promoters and Holders of GDRs and ADRs):**

S. No.	Name	Shareholding		Date	Increase/Decrease in shareholding	Reason	Cumulative shareholding during the year (01.04.20 to 31.03.21)	
		No. of Shares at the beginning (01.04.20)/ End of the year (31.03.21)	% of total share of the Company				No. of Shares	% of total shares of the Company
1	PRATEEK GOEL	50000	4.87	01/04/2021				
				No movement during the year.				
		50000	4.87	31/03/2022				

v) Shareholding of Directors and Key Managerial Personnel:

S. No.	Shareholding of each Directors and each Key Managerial Personnel	Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	Mr. DHIRENDRA KUBER DUBEY, Whole Time Director				
	At the beginning of the year- 01.04.2021	40000	3.89	40000	3.89
	Date wise increase/decrease in Promoters Share holding during the year specifying the reasons for increase/decrease (e.g. allotment/ transfer/ bonus/ sweat equity etc)	0	0	0	0
	At the end of the year-31.03.2022			40000	3.89
2	Mr. NIKHIL KUBER DUBEY, Whole Time Director				
	At the beginning of the year- 01.04.2021	10000	0.97	10000	0.97
	Date wise increase/decrease in Promoters Share holding during the year specifying the reasons for increase/decrease (e.g. allotment/ transfer/ bonus/ sweat equity etc)	0	0	0	0
	At the end of the year-31.03.2022			10000	0.97

3	Mr. SHABBAR HUSSAIN, Independent Director				
	At the beginning of the year- 01.04.2021	0	0	0	0
	Date wise increase/decrease in Promoters Share holding during the year specifying the reasons for increase/decrease (e.g. allotment/ transfer/ bonus/ sweat equity etc)	0	0	0	0
	At the end of the year-31.03.2022			0	0

VI. INDEBTEDNESS -Indebtedness of the Company including interest outstanding/accrued but not due for payment.

(Rs in lakhs)

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	0	0	0	0
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	0	0	0	0
Change in Indebtedness during the financial year				
* Addition	0	0	0	0
* Reduction	0	0	0	0
Net Change	0	0	0	0
Indebtedness at the end of the financial year				
i) Principal Amount	0	0	0	0
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	0	0	0	0

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL-

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

(Rs in lakhs)

S. No.	Particulars of Remuneration	Name of MD/WTD/ Manager			Total Amount (Rs.)
		Mr. Dharendra Dubey	Mr. Nikhil Kuber Dubey	-	
1	Gross salary	Mr. Dharendra Dubey	Mr. Nikhil Kuber Dubey	-	-
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	18.00	18.00	-	36.00
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	-	-	-	-
2	Stock Option	-	-	-	-
3	Sweat Equity	-	-	-	-

4	Commission - as 1.5% of profit - others, specify...	49.00 -	49.00 -	- -	98.00 -
5	Others, please specify Interest	0	-	-	-
	Total (A)	-	-	-	134.00
	Ceiling as per the Act	10% of Net profit for all Executive Directors- Managing & WholeTime Directors i.e. Rs 3.18 Cr			

B. Remuneration to other directors (Nil)

S. No.	Particulars of Remuneration	Name of Directors			Total Amount (Rs)
1	Independent Directors	Mr. SHABBAR HUSAIN	-	-	
	Fee for attending board / committee meetings	0	0	0	0
	Commission	-	-	-	
	Others, please specify	-	-	-	
	Total (1)	0	0	0	0
2	Other Non-Executive Directors				
	Fee for attending board / committee meetings	-	-	-	
	Commission	-	-	-	
	Others, please specify	-	-	-	
	Total (2)	0	0	0	0
	Total (B)=(1+2)	0	0	0	0

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD (Nil)

S. No.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total (Rs)
1	Gross salary	-	-	-	-
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	-	-	-	-
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	-	-	-
2	Stock Option	-	-	-	-
3	Sweat Equity	-	-	-	-
4	Commission	-	-	-	-
	- as % of profit	-	-	-	-
	others, specify...	-	-	-	-
5	Others, please specify	-	-	-	-
	Total	-	-	-	-

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
A. COMPANY					
Penalty					
Punishment					
Compounding					
B. DIRECTORS					
Penalty			NIL		
Punishment					
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty					
Punishment					
Compounding					

For and on behalf of the Board


Nikhil Kuber Dubey
Director
(DIN: 00538049)


Dhirendra Dubey
Director
(DIN: 01493040)

Date: 27-05-2022
Place: Bhopal



ANNEXURE-B TO DIRECTORS' REPORT

**SECRETARIAL AUDIT REPORT
FOR THE FINANCIAL YEAR ENDED 31st MARCH, 2022**

Pursuant to Section 204(1) of the Companies Act, 2013 and Rule no. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

To,
The Members,
3B BLACKBIO BIOTECH INDIA LIMITED
7-C, Industrial Area,
Govindpura,
BHOPAL – 462023

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **3B Blackbio Biotech India Limited**, (hereinafter called the "Company"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2022, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2022 according to the provisions of:

1. The Companies Act, 2013 ('the Act') and the rules made there under;
2. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
3. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
4. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowing

5. Other Laws applicable to the Company;

- a) The Hazardous Wastes (Management and Handling) Rules 1989;
- b) Payment of Bonus Act 1965, & Rules, 1965
- c) Maternity Benefit Act 1961 & Rules
- d) Employees Compensation Act, 1923 & Rules.
- e) Minimum Wages Act, 1948, M.W(C) Rules, 1950
- f) Child Labour (P&R) Act 1986 & Rules.
- g) Payment of Wages Act 1936
- h) Employees PF & Miscellaneous Provisions Act 1952
- i) Industrial Disputes Act, 1947
- j) Indian Contract Act, 1872
- k) Environment Protection Act, 1986 and other environmental laws
- l) Payment of Gratuity Act, 1972
- m) Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act 2013

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that

- The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
- Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.
- Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes. All the decisions have been taken unanimously and no dissent recorded.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period, there are no specific events / actions having a major bearing on the Company's affairs in pursuance of the laws, rules, regulations, guidelines, standards, etc, referred to above.

**For P.K. Rai & Associates
Practicing Company Secretary**



CS PRAVEEN KUMAR RAI

M.No: 6313

C.P.No. 3779

UDIN: F006313D000773301

Date:- 10th August 2022

Place: Bhopal

To,
The Members,
3B BLACKBIO BIOTECH INDIA LIMITED
7-C, Industrial Area,
Govindpura,
BHOPAL – 462023

Our Secretarial Audit Report of even date is to be read along with this letter.

Management's Responsibility

1. It is the responsibility of the management of the company to maintain secretarial records, devise proper systems to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.

Auditor's Responsibility

2. Our responsibility is to express an opinion on these secretarial records, standards and procedures followed by the company with respect to secretarial compliances.
3. We believe that audit evidence and information obtained from the Company's management is adequate and appropriate for us to provide a basis for our opinion.
4. Wherever required, we have obtained the management's representation about the compliance of laws, rules and regulations and happening of events etc.

Disclaimer

5. The secretarial Audit Report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company

For P.K. Rai & Associates
Practicing Company Secretary



CS PRAVEEN KUMAR RAI
M. No: 6313
C.P. No. 3779
UDIN: F006313D000773301

Date:- 10th August 2022
Place: Bhopal

ANNEXURE-C TO DIRECTORS' REPORT

Annual Report on Corporate Social Responsibility (CSR) activities for the Financial Year 2021-22

1. Brief outline of Company's CSR Policy:

As a responsible business, 3B BlackBio Biotech India Limited takes pride in being socially inclined and focuses on sustained and effective Corporate Social Responsibility Projects. Today we define Corporate Social Responsibility as the way a Company balances it's economic, social and environmental objectives while addressing stakeholder expectations and enhancing shareholders value. Our employees are also encouraged to volunteer their time and skills and enjoy the experience of giving back to the communities in which they work.

The Company has identified the projects in a participatory manner, in consultation with the interested communities and in consonance with Schedule VII of the Companies Act, 2013. Arising from this, the focus areas that have emerged are the Rural and Infrastructure Development, providing quality education, preventive health care, sustainable livelihood and environment sustainability. All of our projects of CSR to be carried by the 3B BlackBio Biotech India Limited or through the Trust/Society in accordance with the Act and Rules.

Web Link: <https://www.3bblackbio.com>

2. Composition of CSR Committee:

S. No.	Name of Director	Designation/ Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Shabbar Hussain	Chairman/ Independent Director	4	4
2	Dhirendra Dubey	Member/ Whole Time Director	4	4
3	Nikhil Kuber Dubey	Member/ Managing Director	4	4

3. Web Link: <https://www.3bblackbio.com>

4. Details of Impact Assessment of CSR Projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable (attach the report): Not Applicable

Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the financial year: Rs 0.03 lac

5. Average net profit of the Company as per section 135(5): Rs. 5529.98 lac
6. (a) Two percent of average net profit of the company for preceding three years as per section 135(5): Rs 110.60 Lacs
 (b) Unspent amount of the previous financial year: Nil
 (c) Amount required to be set off for the financial year: Rs 0.03 lac
 (d) Total CSR obligation for the financial year (7a+7b-7c): Rs 110.57 lac
7. (a) CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial Year. (in Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per Section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount	Date of Transfer	Name of the Fund	Amount	Date of Transfer
1,16,86,599/-	Nil		Nil		

(b) Details of CSR amount spent against ongoing projects for the financial year:

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	(9)	(10)	(11)	
Sl. No	Name of the Project	Item from the list of activities in Schedule VII to the Act	Local area (Yes/No)	Location of the project.		Project duration.	Amount allocated for the project (In Rs.)	Amount spent in the current financial year (In Rs.)	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (In Rs.)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation - Through Implementing Agency	
				State	District						Name	CSR registration Number
1	Academic Programming	Promotion of Education and employment enhancing vocational skills	No	West Bengal	Manasawip	Two Years	1,04,000	1,04,000	NIL	Yes	Ramakrishna Mission Ashrama	CSR00002806

		especial ly among the children									
					TOTAL		1,04,000	1,04,000	NIL		

(c) Details of CSR amount spent against other than ongoing projects for the financial year:

(1) Sl. No	(2) Name of the Project.	(3) Item from the list of activities in Schedule VII to the Act.	(4) Local area (Yes/No).	(5) Location of the project.		(6) Amount spent for the project (Rs).	(7) Mode of implementation - Direct (Yes/No)	(8) Mode of implementation - Through implementing agency.	
				State.	District.			Name.	CSR registration number.
1	PM CARES Fund	Contribution to Prime Minister's Citizen Assistance and Relief in Emergency Situations Fund	Yes	New Delhi	New Delhi	1,10,00,000/-	Yes	-	-
2	Promoting health care including preventive health care(During Second wave of Covid-19)	Promoting health care including preventive health care	Yes	Madhya Pradesh	Katni	49,103/-	Yes	-	-
3	Eradicating hunger(During Second wave of Covid-19)	Eradicating hunger	Yes	Madhya Pradesh	Bhopal	6,165/-	Yes	-	-
4	Promoting education	Promoting education	Yes	Madhya Pradesh	Bhopal	1,75,000/-	Yes	-	-

5	Arushi Society	Promoting education	Yes	Madhya Pradesh	Bhopal	3,52,331/-	Yes	-	CSR00006205
				TOTAL		1,15,82,599/-			

(d) Amount spent in Administrative Overheads: Nil

(e) Amount spent on Impact Assessment: Nil

(f) Total amount spent for the Financial Year: 1, 16, 86, 599/-
(8b+8c+8d+8e)

(g) Excess amount for set off: 3,000/-

S. No.	Particular	Amount (in Rs.)
(i)	Two percent of average net profit of the company as per Section 135(5)	1,10,60,000/-
(ii)	Total amount spent for the Financial Year	1,16,83,599/-
(iii)	Excess amount for the Financial Year[(ii)-(i)]	6,23,599/-
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	Nil
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	6,23,599/-

8. (a) Details of Unspent CSR amount for the preceding three financial years:

S. No.	Preceding Financial Year.	Amount transferred to Unspent CSR Account under section 135(6) (in Rs.)	Amount spent in the reporting Financial Year (in Rs.).	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding financial years. (in Rs.)
				Name of the Fund	Amount (in Rs).	Date of transfer.	
-----Not Applicable-----							

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s):

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
S. No.	Project ID.	Name of the Project.	Financial Year in which the project was commenced.	Project duration.	Total amount allocated for the project (in Rs.).	Amount spent on the project in the reporting Financial Year (in Rs).	Cumulative amount spent at the end of reporting Financial Year. (in Rs.)	Status of the project – Completed /Ongoing.
----- Not Applicable -----								

9. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year (asset-wise details):


(a) Date of creation or acquisition of the capital asset(s): **NA**

(b) Amount of CSR spent for creation or acquisition of capital asset: **NA**

(c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc: **NA**

(d) details of the capital asset(s) created or acquired (including complete address and location of the capital asset): **NA**

10. Reasons for failure to spend two per cent of the average net profit as per section 135(5): **NA**



R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE

24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com

INDEPENDENT AUDITOR'S REPORT

To,

The Members of 3B Black Bio Biotech India Limited

Report on the Financial Statements

We have audited the accompanying financial statements of 3B Black Bio Biotech India Limited ('the company') which comprise the Balance Sheet as at March 31, 2022, the Statement of Profit and Loss, (including Other Comprehensive income), Statement of Changes in Equity, Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis of Opinion


We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section, of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the 'ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Key Audit Matter

Key audit matters are those matters that in our professional judgement were of most significance in our audit of the financial statements of the current year. These matters were addressed in the context of our audit of the financial statement as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Other Information ["Information other than the Financial Statements and Auditor's Report thereon"]

The Company's Board of Directors are responsible for the other information. The other information comprises the information included in the board report but does not include the financial statements and our auditor's report thereon.



R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE

24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under Section 133 of the Act.


This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Director's are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE


24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
-

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE

24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

- 1) As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), as amended, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "**Annexure A**" a statement on the matters specified in paragraphs 3 and 4 of the Order.
- 2) As required by section 143 (3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge belief were necessary for the purpose of our audit.
 - b. In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c. The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Statement of Changes in Equity and the Cash Flow Statement dealt with by this Report are in agreement with the books of accounts.
 - d. In our opinion, the aforesaid financial statements comply with the Indian Accounting Standards specified under section 133 of the Act.
 - e. On the basis of written representations received from the directors as on March 31, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "**Annexure B**".
 - g. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.



R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE


24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com

- h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long- term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv. (a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v. (a) The final dividend proposed in the previous year, declared and paid by the Company during the year is in accordance with Section 123 of the Act, as applicable.

(b) The interim dividend declared and paid by the Company during the year is in compliance with Section 123 of the Act.



R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE

24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com

(c) The Board of Directors of the Company have proposed final dividend for the year which is subject to the approval of the members at the ensuing Annual General Meeting. The amount of dividend proposed is in accordance with section 123 of the Act, as applicable

For R.C. BAHETI & CO.

Chartered Accountants

Practising registration No: 403034C



Ranjan Baheti
Ranjan Baheti


(Partner)

Membership No: 400993

Date: 27/05/2022

Place: Bhopal

UDIN: 22400993AMMVG5135




R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE

24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com

“Annexure A” to the Independent Auditors’ Report

Referred to in paragraph 1 under the heading ‘Report on Other Legal & Regulatory Requirement’ of our report of even date to the financial statements of the Company for the year ended March 31, 2022:

- 1) In respect of its fixed assets:
 - (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - (b) The Fixed Assets have been physically verified by the management at reasonable intervals. In our opinion the frequency of verification is reasonable having regard to the size of the company and nature of the assets. To the best of our knowledge, no material discrepancies have been noticed on such verification.
 - (c) No immovable property held in the name of the company.
- 2) In respect of its Inventories:
 - (a) The inventory of finished goods, raw and packing materials and store and spare parts has been physically verified during the year by the management. In our opinion, the frequency of such verification is reasonable.
 - (b) In our opinion and according to the information and explanations given to us, the procedure for the physical verification of inventories followed by the management are reasonable and adequate in relation to the size of the company and the nature of its business. To the best of our knowledge, no material discrepancies have been noticed on such verification.
 - (c) The Company has not been sanctioned working capital limits in excess of Rs. 5 crore, in aggregate, at any points of time during the year, from banks or financial institutions on the basis of security of current assets
- 3) During the year under consideration company has invested Rs. 10,38,98,300/- (equivalent foreign currency GBP 10,15,000/-) in M/s TRUPCR HSB UK (previously known as HS Biolabs UK) and acquired 700 shares . The terms and conditions of investment are not prejudicial to the interest of the company.
- 4) The company has not given any loans, investments, guarantees and security. Hence the provisions of section 185 and 186 of the Companies Act, 2013 are not applicable.
- 5) The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, reporting under clause 3(v) of the Order is not applicable.
- 6) As explained, the Central Government has not prescribed maintenance of cost records under sub-section (1) of section 148 of the Companies Act, 2013 for the products of the company.




R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE

24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com

- 7) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company is generally regular in depositing undisputed statutory dues including Income-Tax, Duty of Customs, Cess, Goods and Services Tax (GST) and any other statutory dues with the appropriate authorities applicable to it except :

S. No.	Relevant Statute	Financial Year	Amount (Rs.)	Forum where dispute is pending
1	Income Tax Act 1961	2017-18	Rs. 6,25,790/-	CIT - Appeals
2	Income Tax Act 1961	2019-20	Rs. 99,24,500/-	CIT - Appeals

- 8) There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.
- 9)
- The Company has not taken any loans or other borrowings from any lender. Hence reporting under clause 3(ix)(a) of the Order is not applicable.
 - The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.
 - The Company has not taken any term loan during the year and there are no outstanding term loans at the beginning of the year and hence, reporting under clause 3(ix)(c) of the Order is not applicable.
 - The Company has not raised funds on short-term basis reporting under clause 3(ix)(d) of the Order is not applicable.
 - On an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
 - The Company has not raised any loans during the year and hence reporting on clause 3(ix)(f) of the Order is not applicable. No term loans availed during the year hence this clause is not applicable.
- 10) (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable.
- (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the Order is not applicable
- 11) (a) No fraud by the Company and no material fraud on the Company has been noticed or reported during the year.



R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE

24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com

- (b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.
- (c) There were no whistle blower complaints received.
- 12) The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable
- 13) In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 with respect to applicable transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.
- 14) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business..
- 15) In our opinion during the year the Company has not entered into any non-cash transactions with its Directors or persons connected with its directors. and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company
- 16) (a) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a), (b) and (c) of the Order is not applicable
- (b) In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly reporting under clause 3(xvi)(d) of the Order is not applicable
- 17) The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- 18) There has been no resignation of the statutory auditors of the Company during the year.
- 19) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when



R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE

24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com

they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- 20) In our opinion and according to the information and explanations given to us, there is no unspent amount of CSR under sub-section (5) of section 135 of the Act pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For R.C. BAHETI & CO.
Chartered Accountants


Firm's registration No: 403034C

Ranjan Baheti
PARTNER



Membership No: 400993

Place: Bhopal
Date: 27/05/2022
UDIN: 22400993AMMVG5135



R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE

24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com

“Annexure B” to the Independent Auditor’s Report of even date on the Financial Statements of 3B BlackBio Biotech India Limited

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of 3B BlackBio Biotech India Limited (“the Company”) as of March 31, 2022 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls


The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the Guidance note) issued by the Institute of Chartered Accountants of India”. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.



R. C. BAHETI & CO.
Chartered Accountants
HEAD OFFICE

24, Zone - II, M. P. Nagar, Near Som Distilleries
Bhopal - 462011
Ph. 0755 - 2557761, 4908690 MOB. 09826282060
Email - rameshchandrabaheti@yahoo.com
ranjanbaheti@gmail.com

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


Opinion

In our opinion and best of the information and according to the explanations given to us the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

For R.C. BAHETI & CO.

Chartered Accountants`

Firm's registration No: 403034C


Ranjan Baheti
PARTNER



Membership No: 400993

Place: Bhopal

Date: 27/05/2022


UDIN: 22400993AMMVG5135

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED
BALANCE SHEET AS AT 31st MARCH 2022

Particulars	Note No.	As at 31-Mar-22	As at 31-Mar-21
ASSETS			
NON-CURRENT ASSETS			
Property , Plant , Equipments	2	3,38,41,174.23	3,02,35,759.19
Intangible Assets	3	-	-
Financial Assets			
(a) Investments	4	92,63,93,208.66	588,137,576.99
(b) Other Financial Assets	5	10,91,37,816.81	109,137,816.81
Other Non Current Assets	6	1,01,117.50	202,235.00
Total Non Current Assets		106,94,73,317.20	72,77,13,387.99
CURRENT ASSETS			
Inventories	7	4,77,45,476.00	2,16,92,375.94
Financial Assets			
(a) Trade Receivables	8	15,63,31,742.26	21,64,88,443.39
(b) Cash and Cash Equivalents	9	1,78,16,297.25	54,81,855.06
(c) Other Bank Balances	10	25,25,75,202.36	32,82,25,878.36
(d) Loans	11	8,36,417.00	9,82,764.00
Other Current Assets	12	9,61,08,652.30	39,12,49,031.49
Total Current Assets		57,14,13,787.17	96,41,20,348.24
TOTAL ASSETS		164,08,87,104.37	169,18,33,736.23
EQUITY AND LIABILITIES			
EQUITY			
Equity Share Capital	13	1,02,75,000.00	1,02,75,000.00
Other Equity	14	150,71,73,316.28	128,19,45,355.86
Total Equity		151,74,48,316.28	129,22,20,355.86
NON CURRENT LIABILITIES			
Deffered Tax Liability	15	1,36,76,146.20	61,82,306.91
Other Non Current Liability	16	17,519.33	2,93,148.52
Total Non Current Liabilities		1,36,93,665.53	64,75,455.43
CURRENT LIABILITIES			
Financial Liabilities			
(a) Trade Payables	17	0.00	94,69,155.94
(b) Other Financial Liabilities	18	25,75,780.00	6,23,500.00
Provisions	19	10,71,69,342.56	38,30,45,269.00
Total Current Liabilities		10,97,45,122.56	39,31,37,924.94
TOTAL EQUITY AND LIABILITIES		164,08,87,104.37	169,18,33,736.23

Notes 1- 26 form integral part of financial statements

For and on behalf of Board of Directors


Dhirendra Dubey
Managing Director
DIN : 01493040


Nikhil Kuber Dubey
Director
DIN : 00538049



In terms of our report of even date
For R.C. Baheti & Co.
Chartered Accountants
Firm Registration No. 403034C


Ranjan Baheti
Partner



Membership No. 400993
UDIN : 22400993AMMVG5135

Place :- Bhopal
Dated :- 27/05/2022

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED
STATEMENT OF PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2022

Particulars	Note No.	For the year ended March 31, 2022	For the year ended March 31, 2021
INCOME			
Revenue from Operations	20	66,82,77,962.83	214,21,35,163.82
Other Income	21	67,61,0,637.87	2,84,25,935.23
TOTAL INCOME (I)		73,58,88,600.70	217,05,61,099.05
EXPENSES			
Cost of raw material and components consumed	22	206,557,076.38	41,66,94,278.68
Purchase of Stock in Trade		10,299,027.36	3,138,526.00
Change in Inventory of Finished Goods	23	(3,453,102.00)	14,70,614.00
Employee benefits expenses	24	19,872,564.19	3,03,40,757.69
Other expenses	25	74,826,127.94	21,52,45,307.04
Depreciation and amortization expenses	26	3,811,522.15	41,53,158.08
TOTAL EXPENSE (II)		31,19,13,216.02	67,10,42,641.49
Profit Before exceptional items and Tax (I-II)		42,39,75,384.68	149,95,18,457.56
Add: Exceptional Item(gain on sale of fixed assets)		-	-
Profit Before tax		42,39,75,384.68	149,95,18,457.56
Tax Expenses			
Current tax		9,81,85,522.00	37,42,06,392.00
Deferred tax		74,93,839.29	31,27,768.55
Previous Year Income Tax		-	6,75,901.84
PROFIT FOR THE YEAR		31,82,96,023.39	112,15,08,395.17
Other Comprehensive Income/Loss			
(i) Items that will not be reclassified to profit and loss:			
Equity instruments at fair value through other comprehensive income		-	104,913.63
(ii) Income tax (expense)/credit relating to items that will not be reclassified to profit or loss			
		-	-
Total Comprehensive Income		-	104,913.63
Total comprehensive income/(loss) for the year		31,82,96,023.39	112,16,13,308.80
EPS		309.78	1,091.59

Notes 1- 26 form integral part of financial statements

For and on behalf of Board of Directors


Dharendra Dubey
Managing Director
DIN : 01493040


Nikhil Kuber Dubey
Director
DIN : 00538049

In terms of our report of even date
For R.C. Baheti & Co.
Chartered Accountants

Firm Registration No. 403034C




Ranjan Baheti
Partner

Membership No. 400993

UDIN : 22400993AMMVG5135

Place :- Bhopal
Dated :- 27/05/2022



M/S 3 B BLACK BIO BIOTECH INDIA LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31 , 2022

PARTICULARS	2022	2021
I. Cash Flow From Operating Activities		
Net Profit/(Loss) as per Statement of Profit & Loss	318,296,023.39	1,121,508,395.17
Add:- Provision for Taxation	105,679,361.29	378,010,062.39
Net Profit before Working Capital Changes	423,975,384.68	1,499,518,457.56
Add:- Depreciation and Amortization	3,811,522.15	4,153,158.08
Less:- Long Term Capital Gain	(1,070,022.73)	-
Interest Earned	(38,502,852.94)	(27,125,751.46)
Gain on investments carried at fair value through profit and loss	(26,325,934.43)	(1,050,894.28)
	361,888,096.73	1,475,494,969.90
Changes In Working Capital		
Less :- Increase in Inventories	26,053,100.06	13,150,710.94
Less:- Increase in Trade Receivables	(60,156,701.13)	158,718,816.08
Less:- Increase in Other Current assets	(8,856,447.63)	9,383,347.75
Less:- Increase in Other Non-Current assets	(101,117.50)	202,235.00
Add:- Increase in Trade Payables	(9,469,155.94)	5,692,190.28
Add:- Increase in Provision	144,943.56	7,648,258.35
Add:- Increase in Other Non-Current Liability	(275,629.19)	291,183.52
Add:- Increase in Other Current Liability	1,952,280.00	290,000.00
Net Profit /(Loss) after Working Capital Adjustment	397,301,701.36	1,307,961,492.28
Less:- Income Tax Paid	(93,653,023.41)	(379,936,954.97)
Previous Year Income Tax Paid	-	(7,972,590.00)
Net Cash Flow from Operating Activities	303,648,677.95	920,051,947.31
II. Cash Flow From Investing Activities		
Loans & Deposits repaid during the year	146,347.00	(353,709.00)
Fixed Assets Purchased	(7,416,937.19)	(16,504,848.56)
Fixed Assets Sold	-	1,150,000.00
Interest Received	39,267,624.80	24,998,517.46
Mutual Funds/Bonds Purchased	(327,152,571.35)	(614,449,062.71)
Bonds Sold/Matured	15,528,124.98	41,489,614.00
Bank balances not considered as Cash & cash Equivalents	75,650,676.00	(424,971,826.33)
Net Cash Flow From Investing Activities	(203,976,735.76)	(988,641,315.14)
III. Cash Flow From Financing Activities		
Interim Dividend (Gross Dividend) 21-22	(77,062,500.00)	-
Dividend (Gross Dividend) 2020-21	(10,275,000.00)	-
Proceed From Issue of Equity Shares	-	-
Net Cash Flow From Financing Activities	(87,337,500.00)	-
Net Increase in Cash & Cash Equivalents	12,334,442.19	(68,589,367.83)
Cash & Cash Equivalents at beginning of the year	5,481,855.06	74,071,222.89
Cash & Cash Equivalents at end of the year	17,816,297.25	5,481,855.06

Cash Flow Statement has been prepared under the indirect method as set out in Ind AS-7

For and on behalf of Board of Directors


Dharendra Dubey
Managing Director
DIN: 01493040


Nikhil Kuber Dubey
Director
DIN: 00538049



In terms of our report of even date

For R.C. Baheti & Co.
Chartered Accountants
Firm Registration No. 403034C


Ranjan Baheti
Partner



Membership No. 400993
UDIN : 22400993AMMVG5135

Place :- Bhopal
Dated :- 27/05/2022

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

Statement of Changes in Equity

For The Year Ended 31st March 2022

A) Equity Share Capital

Particulars	Amount(Rs.)
Balance at 01 April, 2021	1,02,75,000.00
Balance at 31st March, 2022	1,02,75,000.00

B) Other Equity

Particulars	Securities Premium	Retained Earnings	Other Equity	
			Money Received Against Share Warrants	Equity instruments through OCI
Balance as on 01st April 2021	36,000,000.00	124,59,45,355.86	0.00	-
Add:				
Profit for the Year		31,82,96,023.39		
Total Comprehensive income/(loss) for the year	36,000,000.00	156,42,41,379.25	0.00	-
Issue of Equity shares through conversion of preferential share warrants	-		-	
Equity instruments at fair value through other comprehensive income				-
Dividend Paid		(87,337,500.00)		
Previous Year Tax Paid		(5,730,562.97)		
Balance as on 31st March 2022	3,60,00,000.00	147,11,73,316.28	-	-

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

2. PROPERTY, PLANT & EQUIPMENT

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Property, Plant & Equipments	33,841,174.23	30,235,759.19
Total(Rs.)	33,841,174.23	30,235,759.19

3. INTANGIBLE ASSETS

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Intangible Assets	-	-
Total(Rs.)	-	-

4. NON CURRENT INVESTMENTS

PARTICULARS	As at 31.03.2022	As at 31.03.2021
-------------	------------------	------------------

Non-current investments

Bonds - At Cost		
8.15% Bank Of Baroda Perpetual Fund(Including Accrued Interest)	51,866,000.62	51,866,000.62
7.33% Tata Capital Housing Finance Ltd. (Bonds)	20,601,913.00	20,601,913.00
Asirvad Micro Finance Debentures @9.7063%	10,653,472.47	-
Canara Bank 8.50% Perp Bond	20,439,356.61	-
India Grid trust Bonds 7.45%	2,517,893.19	-
Indian Bank Perp Bonds -8.44%	20,311,989.49	-
PNB Perpetual Bonds 8.6%	10,062,585.34	-
SBI Perp Bonds 7.73%	20,899,939.90	-
Shriram Transport Finance Ltd Deb. 7.60% (Including Accrued Interest)	10,717,548.49	-
	168,070,699.11	72,467,913.62

Mutual Funds - At Fair Value

SBI Arbitrage Mutual Fund	-	4,549,489.04
SBI Equity Fund	-	9,908,613.21
Aditya Birla Sun Life Mutual Fund	52,846,748.81	50,335,770.02
Aditya Birla Sun Life Income Fund	53,153,523.31	50,387,220.57
IDFC Banking PSU Debt Mutual Fund	52,694,859.43	50,476,680.49
IDFC Bond Fund- Short term plan	52,733,583.19	50,436,186.08
Kotak Dynamic Bond fund	36,848,285.18	25,147,888.59
Kotak Medium Term Fund	68,923,845.34	25,177,747.83
Kotak - Savings Fund Growth (Reg) Plan	104,097.73	100,638.55
SBI Dynamic Bond Fund	51,670,044.92	50,230,379.20
SBI Magnum Medium Duration Fund- Growth	52,521,112.22	50,076,767.02
SBI Short Term Debt Fund - Reg. Growth	52,080,962.63	50,026,113.75
ICICI Prudential Balance Advantage Fund	53,893,279.98	-
ICICI Prudential Credit Risk Fund Dp- Growth	26,250,983.79	-
	553,721,326.53	416,853,494.35

Government Bonds - At Cost

8.3% National Highway Authority of India Bonds(Including Accrued Int)	19,424,967.79	17,479,297.79
6.95% Power Finance Corporation Non-Convertible Debentures (Including Accrued Interest)	50,656,917.00	50,656,917.00
7.97% REC Perpetual Bonds(Including Accrued Interest)	30,620,998.23	30,679,954.23

TRUPCR HSB JV UK (Previously known as HS Biolabs) (Investment in 700 shares equivalent foreign currency GBP 1015000)	103,898,300.00	-
	204,601,183.02	98,816,169.02
Total	926,393,208.66	588,137,576.99

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

5. Other Financial Assets

PARTICULARS	As at 31.03.2022	As at 31.03.2021
HDFC STDR A/c *	109,137,816.81	109,137,816.81
	109,137,816.81	109,137,816.81

*Bank Term deposit with maturity more than 12 months from balance sheet date

6. Other Non Current Assets

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Wellkang Limited U.K.(Prepaid Expenses) (Biennial Fee)	101,117.50	202,235.00
	101,117.50	202,235.00

7. INVENTORIES

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Inventories of Raw Material,Packing Material and finished goods Total(Rs.)	47,745,476.00	21,692,375.94
	47,745,476.00	21,692,375.94

8. TRADE RECEIVABLES

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Outstanding for a period exceeding six months (Unsecured but Considered good) Others	434,800.25	1,614,469.25
	155,896,942.01	214,873,974.14
Total(Rs.)	156,331,742.26	216,488,443.39

9. CASH AND CASH EQUIVALENTS

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Cash in hand	568,824.84	604,129.38
Indus Ind Bank	14,911.34	15,380.34
SBI Current A/c(Including Auto Swipe FDS)	8,180,065.83	3,007,769.01
State Bank of India (T.T. Nagar) OD A/c	2,558,240.18	193,780.79
HDFC Bank CD A/c	6,494,255.06	1,660,795.54
Total(Rs.)	17,816,297.25	5,481,855.06

10. Other Bank Balances

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Indus Ind STDR A/c*	5,704,131.36	5,325,184.30
Accrued Interest- Indusind Bank*	378,348.00	378,947.06
Accrued Interest- HDFC Bank*	6,002,580.00	-
SBI STDR A/c*	229,500,000.00	312,000,000.00
Accrued Interest- SBI	7,449,863.00	9,643,747.00
HDFC Interim Dividend A/c (2021-22)	1,722,600.00	-
HDFC Final Dividend A/c (2020-21)	229,680.00	-
SBI Interim Dividend A/c (2019-20)	300,000.00	300,000.00
SBI Interim Dividend A/c (2018-19)	140,500.00	140,500.00
SBI Interim Dividend A/c (2017-18)	203,000.00	203,000.00
SBI BG A/c	844,500.00	184,500.00
SBI Forward Contt. Margin STDR	100,000.00	50,000.00
	252,575,202.36	328,225,878.36

*Bank Term deposit with maturity more than 3 months

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

11. DEPOSITS AND ADVANCES

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Deposits others (incl. security deposit with various govt. dept)	645,232.00	604,055.00
Advances to Staff	191,185.00	378,709.00
Total(Rs.)	836,417.00	982,764.00

12. OTHER CURRENT ASSETS

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Other Duties & Taxes	43,251.40	43,251.40
Advance tax and TDS	93,561,540.80	379,841,015.86
TCS (Input Credit)	91,482.61	95,939.11
GST Recievable	-	503,709.48
Cenvat (Excise)	12,391.00	12,391.00
Balance in PLA Account	56,629.00	56,629.00
Income Tax Deposit(2010-11)	6,180.00	6,180.00
Expenses on Merger(under progress)	323,000.00	323,000.00
Advance To Supplier	2,014,177.49	10,100,685.24
MEIS License	-	266,230.40
Total(Rs.)	96,108,652.30	391,249,031.49

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

13. EQUITY SHARE CAPITAL

PARTICULARS	As at 31.03.2022		As at 31.03.2021	
Authorised Share Capital	No. of Share		No. of Share	
Equity Share of Rs.10/- each	1200000	12,000,000.00	1200000	12,000,000.00
Issued Subscribed and Paid up				
Equity Share of Rs.10/- each fully paid up (Previous year Rs.10/- each)	1027500	10,275,000.00	1027500	10,275,000.00
Total(Rs.)		10,275,000.00		10,275,000.00

Note:- 13.1

The reconciliation of the number of shares outstanding is set out below:

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Balance at the commencement of the year	1,027,500.00	627,500.00
Add: Shares issued on conversion of Warrants	-	400,000.00
Balance at the end of the year	1,027,500.00	1,027,500.00

Note:- 13.2

The holders of the equity share are entitled to receive dividends as declared from time to time and are entitled to one vote per share at the meeting of the company .

Note :-13.3

Details of shareholding morethan 5% of the shares

Particulars	As at 31.03.2022		As at 31.03.2021	
	No. of Share	% of Share holding	No. of Share	% of Share holding
M/s Kilpest India Limited , Bhopal	898500	87.45	898500	87.45
M/s 2B Blackbio ,S.L. Spain	29000	2.82	29000	2.82
Shri Nikhil Kuber Dubey	10000	0.97	10000	0.97
Shri Dharendra Dubey	40000	3.89	40000	3.89
Shri Prateek Goel	50000	4.87	50000	4.87
	1027500	100.00	1027500	100.00

14. OTHER EQUITY

PARTICULARS	As at 31.03.2022		As at 31.03.2021	
Surplus :-				
Opening balance	1,245,945,355.86		12,43,32,047.06	
Add:-Profit after tax for the year	318,296,023.39		112,16,13,308.80	
Less: Advance tax	5,730,562.97		-	
Less: Final Dividend	10,275,000.00		-	
Less: Interim & Final Dividend	77,062,500.00	1,471,173,316.28	-	1,245,945,355.86
Equity instruments through OCI		-		-
Securities Premium Account		36,000,000.00		36,000,000.00
Total (A)		1,507,173,316.28		1,281,945,355.86

Security premium

The amount received in excess of face value of the equity shares, in relation to issuance of equity, is recognised in Securities Premium Reserve.

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

15. DEFERRED TAX LIABILITY

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Opening	6,182,306.91	3,054,538.36
Add : Current year's	7,493,839.29	3,127,768.55
Total(Rs.)	13,676,146.20	6,182,306.91

16. OTHER NON CURRENT LIABILITY

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Security Deposit	1,965.00	1,965.00
Nirman Share Brokers Pvt. Ltd.	(6,864.47)	(12,597.06)
Advance From Customers	22,418.80	303,780.58
Total(Rs.)	17,519.33	293,148.52

17. TRADE PAYABLE

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Trade Payable	-	2,819,526.07
Other Payables	-	6,649,629.87
Total(Rs.)	-	9,469,155.94

18. OTHER FINANCIAL LIABILITIES

PARTICULARS	As at 31.03.2022	As at 31.03.2021
Unclaimed Dividend (18-19)	130,500.00	130,500.00
Unclaimed Dividend (17-18)	203,000.00	203,000.00
Unclaimed Dividend (19-20)	290,000.00	290,000.00
Unclaimed Dividend (20-21)	229,680.00	-
Unclaimed Dividend (21-22)	1,722,600.00	-
Total (Rs.)	2,575,780.00	623,500.00

19. PROVISIONS

PARTICULARS	As at 31.03.2022	As at 31.03.2021
TDS Payable	956,918.00	898,110.00
TCS Payable	-	47,943.00
Professional Tax	36,250.00	27,824.00
Audit fees	100,000.00	100,000.00
Provision for Income Tax	98,185,522.00	374,206,392.00
GST Payable	349,178.95	-
Performance Bonus (Covid 19) Payable	2,608,000.00	7,765,000.00
Other Payables	4,933,473.61	-
Total (Rs.)	107,169,342.56	383,045,269.00

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

20. REVENUE FROM OPERATIONS

PARTICULARS	For the year ended 31.03.2022	For the year ended 31.03.2021
Sales of products		
Trading	6,376,803.99	4,248,631.00
Diagnostics Kits	616,934,751.74	2,135,172,502.38
Life Sciences	1,510,627.75	1,230,649.00
Export Sale	43,455,779.35	1,483,381.44
Total(Rs.)	668,277,962.83	2,142,135,163.82

21. OTHER INCOME

PARTICULARS	For the year ended 31.03.2022	For the year ended 31.03.2021
Interest on Fixed Deposit	20,737,768.80	21,568,779.46
Interest income on Bonds	17,765,084.14	5,556,972.00
Custom Duty Drawback	322,070.00	42,885.00
Freight Charges Export	1,360,318.00	126,166.60
Freight Charges Collected	-	18,400.00
Gain on investments carried at fair value through profit and loss* (Net of loss on sale of Investment)	26,325,934.43	1,050,894.28
Exchange gain (Net)**	29,439.77	61,837.89
Gain on Sale of Investment	1,070,022.73	-
Total(Rs.)	67,610,637.87	28,425,935.23

*Gain on investments carried at fair value through profit and loss 26,325,934.43
Less: Loss on sale of current investment -

26,325,934.43

Exchange gain (Net)**

Exchange gain 29,439.77

Less: Exchange Loss -

29,439.77

22. RAW MATERIAL CONSUMED

PARTICULARS	For the year ended 31.03.2022	For the year ended 31.03.2021
Opening Stock of Raw Material	19,753,060.94	5,131,736.00
Add:- Purchased during the year	229,157,074.44	431,315,603.62
Less:- Closing Stock of Raw Material	42,353,059.00	19,753,060.94
Total(Rs.)	206,557,076.38	416,694,278.68

23. CHANGE IN INVENTORY OF FINISHED GOODS

PARTICULARS	For the year ended 31.03.2022	For the year ended 31.03.2021
Opening stock of finished goods	1,939,315.00	3,409,929.00
Add: Purchase of Finished Goods	-	-
Less : Closing stock of finished goods	5,392,417.00	1,939,315.00
Total(Rs.)	(3,453,102.00)	1,470,614.00

24. EMPLOYEE BENEFIT EXPENSE

PARTICULARS	For the year ended 31.03.2022	For the year ended 31.03.2021
Salary and other emoulements	19,158,775.00	15,580,733.00
Staff and labour welfare	713,789.19	452,524.69
Performance Bonus	-	14,307,500.00
Total(Rs.)	19,872,564.19	30,340,757.69

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

25. OTHER EXPENSE

PARTICULARS	For the year ended 31.03.2022	For the year ended 31.03.2021
Advertisement & Publicity	1,140,839.00	1,042,985.52
Audit Fees	100,000.00	100,000.00
Bank Commission & Charges	269,178.56	1,447,080.46
Carrige Outward Expenses	8,116,744.30	6,770,511.86
Commission On Sales	150,000.00	111,396,457.00
Commission to Director	9,800,000.00	34,800,000.00
Computer Maintenance	74,526.14	43,767.07
Conveyance	500,728.00	1,049,001.00
Conference Expense	1,465,011.00	697,220.00
CSR	12,735,282.00	896,715.00
Garden Maintainence	141,960.00	123,890.00
General Maintainence	437,973.17	394,973.23
Electricity Exp	1,350,000.00	996,952.00
Fuel & Power	29,082.36	135,223.00
Festival Expenses	359,628.00	584,713.44
Insurance Expenses	41,102.00	574,196.00
Lab Expenses	30,000.00	127,749.00
LD Deducted By Hites	-	2,148,046.00
Legal & Professional Fees	2,036,502.00	868,720.00
Machinery Maintenance	90,190.00	287,090.14
Medical Expenses	48,307.00	80,286.11
Miscellaneous Expenses	255,550.00	398,269.26
Office & General Expenses	1,229,193.92	1,166,280.63
Packing & Forwarding	4,007,939.82	4,213,218.10
Postage	138,372.32	36,294.74
Packing Material (Freight)	44,125.00	268,749.17
Printing/Stationery/Photocopy Expenses	411,019.00	589,548.00
Packing Material(Ice and Other)	32,400.00	1,343,580.94
Rates taxes and fees	23,058,958.93	37,446,686.22
Rent Expenses	775,320.00	860,256.00
Research and Development Expenses	3,544,202.05	2,123,715.00
Staff Skill Development	112,000.00	-
Selling,Distribution & Sales Promotion Expenses	670,939.06	659,428.58
Stores & Spare Parts Consumed	298,583.30	22,758.83
Subscription &Online advertisement	139,678.49	139,361.63
Telephone Expenses	43,033.35	38,329.29
Travelling & Conveyance Expenses	1,147,777.10	1,373,211.30
Round Off	(17.93)	42.52
Total (Rs.)	<u>74,826,127.94</u>	<u>215,245,307.04</u>

26. DEPRICIATION & AMMORTISATION EXPENSE

PARTICULARS	For the year ended 31.03.2022	For the year ended 31.03.2021
Depreciation on tangible assets	3,811,522.15	4,153,158.08
Total(Rs.)	<u>3,811,522.15</u>	<u>4,153,158.08</u>

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

Other Payables

Particulars	Amount As at 31.03.2022
Dhl Express Ltd.	11,782.00
Glam Venture Bhopal	5,444.78
Total	17,226.78

Other Payables for Expenses

Particulars	Amount As at 31.03.2022
G.C.Lifesciences	1,075,758.00
Ravi Kumar	360,000.00
Dhirendra Dubey	1,357,940.50
N K Dubey	791,510.50
Staff & Directors	1,331,038.31
Total	4,916,247.31

Total 4,933,474.09

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

Other Payables

Advance from Customers

Particulars	Amount As at 31.03.2022
Modern Scientific Corporation	21,952.00
Modern X-Ray Pathology	396.00
Premas Biotech Pvt. Ltd.	70.80
Total	22,418.80

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

Trade Receivables

Particulars	Amount	
	As at 31.03.2022	As at 31.03.2022
	Less than 6 months	More than 6 months
Abhilash Tiwari	1,557.00	-
Alayza Life Science	88.00	-
Arts & science college, pullgaon	-	2,266.55
BIOMART, Delhi	-	68,500.00
Cancer Institute	-	7,376.00
Central India Institute Of Medical sciences	88,907.00	-
Chemi-Health Diagnostics	-	774.20
Chief Medical Officer CMS	-	7,840.00
Chirayu Medical College & Hospital Bhopal	12,964.00	-
Deep Enterprises	18,278.80	-
Dev Enterprises	53,424.00	-
Directorate Of Disaster Management , Port Blair	-	9,188.00
Genophyll Enterprises	5,003,339.00	-
Helixmoldx Labs Pvt Ltd	143,113.60	-
Hiya Scientific Solutions	244,664.00	-
HS Biolabs Ltd	3,925,418.60	-
Kilpest India Ltd. - Export	4,347,178.52	-
KR Instruments & chemicals	23,912.00	-
LMMFs- Deenanath Mangeskar Hospital & Res. Centre	192,304.32	-
Malabar Cancer Centre	1,604,103.00	-
Miscellaneous Debtors	22,559.66	-
Neo Science Equipment & Chemicals trading LLC	10,879.48	-
New India Traders	-	49.00
Regene Biologics	236,190.27	-
Reliance Life Sciences Pvt Ltd	193,536.00	-
Sai Aurobindo Medical college & PG Institute	62,999.80	-
Scientific Research & Instrument	-	3,859.50
Shayadri speciality labs	198,906.84	-
SNM Hospital, Leh	-	13,305.00
Sodani hospitals & diagnostics Pvt Ltd	45,668.00	-
Swami Ramanand Teerth Rural Govt. Medical College	-	23,722.00
Vela Operations Singapore Pte. Ltd	4,575,021.60	-
Vela Research Singapore Pte. Ltd	1,034,697.10	-
Vilasrao Deshmukh Govt. Institute of Medical Sciences	-	297,920.00
Virom Healthcare Pvt Ltd	92,806.00	-
Vivid Global Technologies	123,505,509.42	-
VWR International Gmbh	10,258,916.00	-
Total(B)	155,896,942.01	434,800.25
Total Trade Receivables(A+B)		156,331,742.26
Trade receivables more than six months		434,800.25
Others		155,896,942.01

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

Advance to Supplier

Particulars	Amount As at 31.03.2022
Baadshah recovery agency Mumbai	30,000.00
Biolegio B.V.Netherlands.	373,741.00
Dayal trading Co.	2,603.00
Excellent Forwarders	8,024.82
Invitrogen Bioservices India P Ltd	69,983.45
New India Assurance Co. Ltd.	4,073.00
Qiagen India Pvt Ltd ,New Delhi	95,963.16
Sahagene Hyderabad	11,414.40
Sangon Biotech (Shanghai) Co. Ltd	708,262.66
Solar Square Energy Pvt Ltd	710,112.00
	2,014,177.49

3 B BLACKBIO BIOTECH INDIA LIMITED
PROPERTY, PLANT & EQUIPMENT AND DEPRECIATION AS ON 31.03.2022

S.no	Particular	Gross Block			Depreciation			Net Block			
		Balance as on 01.04.2021	Addition during the year	Deductions/ Adjustment	Balance as on 31.03.2022	As on 01.04.2021	For the Year	Deductions/ Adjustment	Total	As on 31.03.2022	As on 31.03.2021
1	Electrical Equipments	593,138.45	219,091.64	-	812,230.09	84,691.96	65,969.57	-	150,661.53	661,568.56	508,446.49
2	Equipments	535,648.09	-	-	535,648.09	463,467.09	18,589.05	-	482,056.14	53,591.95	72,181.00
3	Furniture	564,664.00	616,487.73	-	1,181,151.73	174,367.89	66,344.40	-	240,712.29	940,439.44	390,296.11
4	Computer	1,031,548.77	344,263.92	-	1,375,812.69	656,053.14	97,853.93	-	753,907.07	621,905.62	375,495.63
5	Computer(R&D)	286,577.13	-	-	286,577.13	159,724.65	90,749.42	-	250,474.07	36,103.06	126,852.48
6	Lab Equipments	1,878,722.62	-	-	1,878,722.62	847,686.26	188,352.71	-	1,036,038.97	842,683.65	1,031,036.36
7	R&D Equipments	31,623,007.67	6,237,093.90	-	37,860,101.57	4,857,265.77	3,220,305.18	-	8,077,570.95	29,782,530.62	26,765,741.90
8	Plant & Machinery	1,000,387.68	-	-	1,000,387.68	34,678.46	63,357.89	-	98,036.35	902,351.33	965,709.22
	TOTAL	37,513,694.41	7,416,937.19	-	44,930,631.60	7,277,935.22	3,811,522.15	-	11,089,457.37	33,841,174.23	30,235,759.19

Figures of Previous Years	22,158,845.85	16,504,848.56	1,150,000.00	37,513,694.41	4,382,787.64	2,895,147.58	-	7,277,935.22	30,235,759.19	17,776,058.21
---------------------------	---------------	---------------	--------------	---------------	--------------	--------------	---	--------------	---------------	---------------

S.no	Particular	Gross Block			Depreciation			Net Block		
		Balance as on 01.04.2021	Addition during the year	Deductions/ Adjustment	Balance as on 31.03.2022	As on 01.04.2021	For the Year	Total	As on 31.03.2022	As on 31.03.2021
1	Technology Fees	7,548,063.00	-	-	7,548,063.00	7,548,063.00	-	7,548,063.00	-	-
	TOTAL	7,548,063.00	-	-	7,548,063.00	7,548,063.00	-	7,548,063.00	-	-

Figures of Previous Years	7,548,063.00	-	-	7,548,063.00	6,290,052.50	1,258,010.50	7,548,063.00	-	1,258,010.50
---------------------------	--------------	---	---	--------------	--------------	--------------	--------------	---	--------------

3B BLACKBIO BIOTECH INDIA LIMITED

Notes to the Financial Statements for the year ended 31st March 2022.

1. Significant Accounting Policies

1.1 Basis of Preparation

The financial statements have been prepared on the accrual basis and historical cost basis. There are certain financial assets and liabilities which are required to be measured at fair value amount. The financial statements of the Company have been prepared to comply with the Indian Accounting Standard ('Ind AS'), including the rules notified under relevant provisions Companies Act, 2013.

1.2 Use of Estimates

The presentation of financial statements in conformity with generally accepted accounting principles requires the management to make estimates and assumption that affect the reported amounts of assets & liabilities, expenses and disclosure of contingent liabilities .Such estimates and assumption are based on the management's evaluation of relevant facts and circumstances as on the date of financial statements.

1.3 Summary of Significant Accounting Policies

(a) Property, plant and equipment

Property, plant and equipment are stated at cost, net of recoverable taxes, trade discount and rebates less accumulated depreciation and impairment loss. Costs directly attributable to acquisition are capitalized until the property, plant and equipment are ready for use, as intended by the Management. The Company depreciates property, plant and equipment over their estimated useful lives using the straight-line method. The estimated useful lives of assets are as follows:

Electrical Equipment's	10 years
Equipment's	5 Years
Furniture	10 Years
Computer(including computers used in R&D) ⁽¹⁾	3 Years
Lab Equipment's	10 Years
R&D Equipment's ⁽¹⁾	10 Years

⁽¹⁾Based on technical evaluation, the Management believes that the useful lives as given above best represent the period over which the Management expects to use these assets. Hence, the useful lives for these assets is different from the useful lives as prescribed under Part C of Schedule II of the Companies Act, 2013.

(b) Inventories

Inventories are valued at Cost.

(c) Impairment of non-financial Assets-

Impairment is reviewed and recognized in the event changes and circumstances indicate that the carrying amount of any property, plant and equipment and intangible assets or group of assets, called cash generating units (CGU) is not recoverable. Difference between the carrying amounts and recoverable value shall be recognized as an impairment loss in the Statement of Profit & Loss.

(d) Employee Benefits

Short Term Employee Benefits

The undiscounted amount of short term employee benefits expected to be paid in exchange for the services rendered by employees are recognized as an expense during the period when employees render the services.

Post-Employment Benefits

No employees completed the specified period of service hence no provision is made for gratuity.

(e) Tax Expenses

Tax Expenses comprises current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income tax Act, 1961 enacted in India and tax laws prevailing in respective tax jurisdiction where the company operates. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date.

Tax is recognized in the Statement of Profit and Loss, except to the extent that it relates to items recognized in the comprehensive income or in equity. In which case, the tax is also recognized in other comprehensive income or equity.

(f) Foreign Currencies Transactions

Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of transaction.

(g) Revenue recognition

Revenue is recognized on completion of Sales of goods or rendering services. Sale is exclusive of GST and packing and forwarding charges collected from customers.

(h) Financial Instruments

Accounting policy

Initial recognition:

The Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are recognized at fair value on initial recognition, except for trade receivables which are initially measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, which are not at fair value through profit or loss, are added to the fair value on initial recognition. Regular way purchase and sale of financial assets are accounted for at trade date.

Subsequent measurement:

Non-derivative financial instruments -

(i) Financial assets carried at amortized cost: A financial asset is subsequently measured at amortized cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding

(ii) Financial assets at fair value through other comprehensive income: A financial asset is subsequently measured at fair value through other comprehensive income if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. The Company has made an irrevocable election for its investments which are classified as equity instruments to present the subsequent changes in fair value in other comprehensive income based on its business model.

(iii) Financial assets at fair value through profit or loss: A financial asset which is not classified in any of the above categories is subsequently fair valued through profit or loss.

(iv) Financial liabilities: Financial liabilities are subsequently carried at amortized cost using the effective interest method, except for contingent consideration recognized in a business combination which is subsequently measured at fair value through profit or loss. For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

Fair value of financial instruments:

In determining the fair value of its financial instruments, the Company uses a variety of methods and assumptions that are based on market conditions and risks existing at each reporting date. The methods used to determine fair value include discounted cash flow analysis, available quoted market prices and dealer quotes. All methods of assessing fair value result in general approximation of value, and such value may never actually be realized.

(i) Depreciation

Depreciation on property, plant and equipment is provided using straight line method based on useful life of the assets prescribed in Schedule II to the Companies Act, 2013. The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively.

(k) Contingent liability: i) One Performance Bank Guarantee amounting to Rs 8,44,500/- (against 100% margin in form of STDR). ii) I.T. Appeals pending before CIT (Appeals) F.Y 2017-18 & F.Y. 2019-20 total amount in appeal Rs 1,05,50,290/-, the Company is confident that the appeals will be decided in its favour.

(l) Previous year figures have been regrouped and rearranged wherever necessary to meet current year presentational requirement.

(m) Remuneration to Statutory Auditors

Fees for the Statutory Audit is Rs. 1.0 Lakh

(p) Dividend:

The final dividend on shares is recorded as a liability on the date of approval by the shareholders and interim dividends are recorded as a liability on the date of declaration by the Company's Board of Directors. Income tax consequences of dividends on financial instruments classified as equity will be recognized according to where the entity originally recognized those past transactions or events that generated distributable profits.

Particulars	Year ended 31/03/2022
Final dividend for fiscal 2021	- 1,02,75,000/-
Interim Dividend for fiscal 2022	7,70,62,500/-

(q) Interest income on bonds amounting to Rs. 1,77,65,084.14/- includes sum of Rs. 47,44,900/- being tax free in nature, details are as under:

Particulars	Amount (Rs)
National Highway authority Of India Bonds	12,69,900/-
Power Finance Corporation Ltd Non-Convertible Debentures	34,75,000/-
Total	47,44,900/-

(r) **Estimation of uncertainties relating to the global health pandemic from COVID-19 ("COVID-19"):** The Company has considered the possible effects that may result from the pandemic relating to COVID-19 in the preparation of these financial statements including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the Company has, at the date of approval of these financial statements, used internal and external sources of information including credit reports and related information and economic forecasts and expects that the carrying amount of these assets will be recovered. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of these financial statements.

(s) **Consolidation of Accounts**

During the year company has acquired 700 shares out of total 1000 shares of TRUPCR HSB UK (Earlier known as H.S. Biolabs United Kingdom) for Rs. 10,38,98,300/- (equivalent foreign currency GBP 10,15,000) shown under the head Non-Current Investment. A non-UK company cannot be a legal entity for PSC (person with significant control) purpose, unless the person with significant control has been identified and approved by UK Company House. Largest shareholder of holding company identified on 28-03-2022 and approved on 01-04-2022 under relevant laws of UK. Whole process of investment completed on 01/04/2022, hence consolidation is not done in current year.

The company has informed all shareholders including those otherwise entitled to vote and no objection have been raised.

(t) **Related Party Disclosure:**

Holding Company

M/s Kilpest India Ltd.

Key Management Personnel and their relatives

Shri Dharendra Kuber Dubey	- Managing Director
Shri Nikhil Kuber Dubey	- Whole Time Director
Smt. Anamika Dubey	- Wife of Shri Dharendra Kuber Dubey
Smt. Mithila Dubey	- Wife of Late Shri Ram Kuber Dubey
Master Raghav Dubey	- Son of Dharendra Dubey
Kumari Ragini Dubey	- Daughter of Nikhil Dubey
Master Rishab Dubey	- Son of Dharendra Dubey


Transaction with related parties:

	Transactions (01/04/2020 to 31/03/2021)	Holding Company (Kilpest India Ltd.)	Associate Concerns (2B Blackbio S.L. Spain)	Key Management & Relatives	Vivid Global Technologies (Prop. Shri Prateek Goel)
1.	Premises Rent	7,75,320/-			
2.	Power & Electricity	13,50,000/-			
3.	Salary Expense	15,75,000/-		36,00,000/-	
4.	Travelling & Conference Exp.				
5.	License Fees and Other Fees	2,23,57,445/-			
6.	Commission to Director			98,00,000/-	
7.	Sale of Goods	1,60,75,600/-			57,92,09,742/-
8.	Discount Allowed.				1,31,42,018/-
9.	Purchase of Goods				69,68,283/-
10.	Purchase of Fixed Assets				23,10,000/-

(q) Additional Information:

Particulars		2021-22	2020-21
a)	Consumption of Raw Material	Rs. 20,65,57,076/-	Rs. 41,66,94,278.68
b)	Value of Stores and Spares Parts.	-	-
c)	C.I.F. Value of Imported goods	Rs. 7,17,71,877/-	Rs. 11,80,07,351.19
d)	Remittance in foreign exchange	€ 1,53,384.98 \$ 6,39,737.46 £ 1,35,189.42	€ 7,14,068.47 \$ 7,51,619.27 £ 2,015.00
e)	Earning in foreign exchange	£ 60,755.60 \$ 1,55,179.40 In INR 1,75,12,068.00	£ 17,726.30 In INR 16,81,930.00

GLOBAL PRESENCE



3B BlackBio Biotech India Ltd.

An ISO 13485:2016 Certified Company

7-C, Industrial Area, Govindpura, Bhopal-462023 (M.P.) INDIA Ph.: +91 9810562700, 9691680693, +91755 4076518
E: prateek@3bblackbio.com, info@3bblackbio.com, enquiry@3bblackbio.com W.: www.3bblackbio.com

Follow us at:

